Review of the Study on Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) Background and Research Question Acute Lymphoblastic Leukemia (ALL) is the most common form of leukemia in children. Current treatment strategies include risk-based induction therapy, response-adapted post-induction therapy,...

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...

Academic Background and Problem Acute lymphoblastic leukemia (ALL) is a malignant hematologic disease, particularly challenging to treat in older patients, with limited treatment options and poor outcomes. Traditional chemotherapy regimens yield long-term survival rates of only 20%-30% in elderly patients. Therefore, finding more effective and bett...